70% DEXTROSE INJECTION USP SOLUTION

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

DEXTROSE

Saadav alates:

BAXTER CORPORATION

ATC kood:

B05BA03

INN (Rahvusvaheline Nimetus):

CARBOHYDRATES

Annus:

70G

Ravimvorm:

SOLUTION

Koostis:

DEXTROSE 70G

Manustamisviis:

INTRAVENOUS

Ühikuid pakis:

500/1000/2000/3000ML

Retsepti tüüp:

Ethical

Terapeutiline ala:

CALORIC AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0102181015; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

1999-03-05

Toote omadused

Page 1 of 14
PRESCRIBING INFORMATION
50% DEXTROSE INJECTION, USP
70% DEXTROSE INJECTION, USP
IN PHARMACY BULK PACK
IV Fluid and Nutrient Replenisher
Baxter Corporation
Mississauga, Ontario L5N 0C2
Canada
Date of Revision:
November 21, 2018
Submission Control No: 220929
Baxter and Viaflex are trademarks of Baxter International Inc
.
Page 2 of 14
50% DEXTROSE INJECTION, USP/
70% DEXTROSE INJECTION, USP
NOT FOR DIRECT INFUSION
IN PHARMACY BULK PACK
SUMMARY PRODUCT INFORMATION
50% Dextrose Injection, USP and 70% Dextrose Injection, USP are
sterile, nonpyrogenic,
hypertonic solutions for fluid replenishment and caloric supply in a
Pharmacy Bulk Package. A
Pharmacy Bulk Package is a container of sterile preparation for
parenteral use that contains many
single doses. The contents are intended for use in a pharmacy
admixture program and are
restricted to the preparation of admixtures for intravenous infusion.
They contain no
antimicrobial agents. Composition, osmolarity, pH, and caloric content
are shown in Table 1.
TABLE 1. PRODUCT INFORMATION.
***
DEX
USP
G/L
OSMOLARITY
(MOSMOL/L)
*KCAL
/L
**KJ/
L
PH
CODE
VOLUM
E
50%
DEXTROSE
INJ USP
500
2520
1710
7147.8
4.0
2B0256
2000 mL
70%
DEXTROSE
INJ USP
700
3530
2380
9948.4
4.0
2B0296
2000 mL
70%
DEXTROSE
INJ USP
700
3530
2380
9948.4
4.0
JB0297
3000 mL
* Dex = 3.4 kcal/g
** 1 kcal = 4.18 kJ
*** the dextrose is purified from corn and may contain fructose
.
The structural formula of Dextrose Hydrous, USP is:
Page 3 of 14
The VIAFLEX plastic container is fabricated from a specially
formulated polyvinyl chloride (PL
146 Plastic) with di-2-ethylhexyl phthalate (DEHP) as a plasticizer.
Exposure to temperatures
above 25˚C during transport and storage will lead to minor losses in
moisture content. Higher
temperatures lead to greater losses. It is unlikely that these minor
losses will lead to clinically
significant changes within the expiration period. The amount of water
that can permeate from
inside the container into the overwrap is insufficient to affect the
solution significantly.